Sobi's Q3 2026 Financial Report Signals Strong Growth Trajectory

On October 27, 2026, Swedish Orphan Biovitrum AB (Sobi®) announced its third-quarter report for 2026, revealing impressive financial results that underline the company's robust growth momentum. The total revenue for the quarter showed a significant increase of 16% at constant exchange rates (CER) and 17% at actual rates, amounting to SEK 9,124 million, up from SEK 7,776 million in the same period last year. This remarkable performance has contributed to a year-to-date growth of 23% at CER, highlighting Sobi's effective strategies in navigating the competitive pharmaceutical landscape.

Key Highlights of Q3 2026 Financial Performance

Strong Revenue Growth in Hematology

One of the most notable aspects of Sobi’s recent performance is the remarkable increase in revenue from its hematology segment. Revenue in this category soared by 29% at CER, reaching SEK 6,171 million, substantially driven by robust sales of Altuvoct, which alone generated SEK 1,729 million compared to SEK 769 million a year earlier. Additionally, sales of Doptelet were also strong, reporting SEK 1,829 million against SEK 1,408 million last year. This growth can be attributed to the increasing demand and positive market reception of these vital products in treating complex blood disorders.

Challenges in Immunology

Conversely, the immunology segment experienced a decline, with a decrease of 6% at CER to SEK 2,525 million, down from SEK 2,658 million previous year. This downturn was primarily due to lower quarterly revenue from Beyfortus royalties, which fell to SEK 732 million from SEK 1,166 million. However, this decline was partially mitigated by strong sales of Gamifant and Kineret, achieving SEK 834 million and SEK 959 million, respectively. Sobi's balancing act in these segments highlights the unpredictability of pharmaceutical revenue streams amidst changing market dynamics.

Revenue from the Strategic Portfolio

Sobi also reported impressive growth from its strategic portfolio, which rose by 25% at CER, resulting in SEK 6,298 million, up from SEK 5,001 million last year. This indicates a successful expansion and execution of its long-term strategies aimed at embracing innovative treatments and addressing unmet medical needs across various therapeutic areas.

Adjusted EBITA and Profitability Metrics

Despite the overall revenue increase, the adjusted EBITA margin saw a slight dip to 45% from last year’s 47%. The adjusted EBITA itself was SEK 3,990 million, representing a margin of 44%. Meanwhile, earnings per share (EPS) showed a rebound; before dilution, it was SEK 6.76, a significant improvement from -8.40 in the same quarter last year.

Looking Ahead: Updated Financial Outlook for 2026

As part of Sobi's commitment to transparency and forward-looking communication, the management provided an update on expectations for the remainder of 2026. The company anticipates revenue will continue to grow by the high teens to low 20s percent at CER, an adjustment from a previous expectation of mid- to high-teens. The adjusted EBITA margin is expected to stabilize in the mid- to high-thirty percent range. Such projections underscore Sobi's confidence in its strategic initiatives and operational effectiveness.

Leadership Transition

In a strategic move following this quarter's earnings report, Sobi announced that CEO Guido Oelkers will step down by the end of January 2027. This leadership transition marks a pivotal moment in the company’s evolution, aiming to infuse new insights into Sobi's future trajectory.

Conclusion

The third-quarter results not only reflect Sobi's strong market presence but also highlight the company's focus on delivering impactful medical solutions for rare diseases. With significant achievements in hematology, coupled with the challenges faced in immunology, Sobi is poised for continued success as it navigates the complexities of the pharmaceutical landscape. Investors, analysts, and the broader market await further developments as Sobi unveils its next strategic moves in the coming months. As the company continues to evolve, its commitment to transforming the lives of patients remains at the forefront of its mission.

For those interested in further details, Sobi will host a conference call on the announcement date at 1500 CET, with comprehensive insights into the financial figures discussed, providing a platform for interaction and clarification on these exciting numbers.